The company reported strong earnings in the second quarter of 2025. It posted revenue of $11.1 billion, which showed a 7.37% ...

Abbott Laboratories (NYSE:ABT) is one of the stocks that Jim Cramer shed light on. Commenting on the company’s recent ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but the stock still ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

Abbott Laboratories closed 6.52% below its 52-week high of $141.23, which the company reached on March 4th.

Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...

Abbott Labs was selling at roughly $21 per share in June 2009. If you had invested in Abbott in 2008, when the stock's average price was $25, and started with $1,000, you would have had enough to ...

Abbott Laboratories reported $1 billion in fourth quarter profits despite an “expected year-over-year decline in Covid-19 testing-related sales,” the company said Wednesday.

Abbott Laboratories first quarter profits eclipsed $2.4 billion thanks to a surge in sales of Covid-19 diagnostic tests as demand grew with the spread of the Omicron variant earlier this year.